IP Library Granted Patent US 9,597,429
Granted Patent B2
US 9,597,429 · App. 14/274,156 · Granted Mar 21, 2017

Cell-free tissue replacement for tissue engineering

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,597,429
App. No.
14/274,156
Granted
Mar 21, 2017
Kind
B2
Abstract

The present invention is a natural, cell-free tissue replacement that does not require difficult or extensive preparation made by washing tissue replacement in a solution including one or more sulfobetaines and an anionic surface-active detergent and washing the tissue replacement in serial solutions of the buffered salt to remove excess detergent. The natural, cell-free tissue replacement may be a nerve graft that supports axonal regeneration, guides the axons toward the distal nerve end and/or is immunologically tolerated. Other forms of the invention are a composition and kit prepared by the method of making a native, cell-free tissue replacement. The present invention may be modified for use in diagnostic, therapeutic, and prophylactic applications.

Claims (44)

1. A method for preparing a native, nerve cell-free tissue replacement nerve graft comprising the steps of:

soaking the nerve graft for at least six hours in a solution comprising sulfobetaine;

washing the nerve graft in one or more solutions of a buffered salt;

extracting the nerve graft in a mixture of one or more sulfobetaines with an anionic surface-active detergent; and

washing the nerve graft in one or more solutions of a buffered salt to remove the excess anionic surface-active detergent, wherein the nerve graft is immunologically tolerated when implanted.

2. The method of claim 1 , further comprising the step of:

adhering one or more components to the nerve graft before storing, wherein the components are selected from the group consisting of a cell, a polymer, a bioactive compound, and combinations thereof.

3. The method of claim 2 , wherein the cells are obtained from a donor, a host, from cell culture from a donor or a host, or cell cultures of established cells, tissue cells, or transformed cell lines.

4. The method of claim 2 , wherein the bioactive compound is selected from the group consisting of a drug, protein, peptide, polysaccharide, fatty acid, nucleic acid, oligonucleotide, detectable agent, organic molecules, inorganic molecules or salts and combinations thereof that include natural or synthetic analogs, derivatives, or mimetic versions of the bioactive compound for therapeutic, prophylactic and diagnostic purposes.

5. The method of claim 2 , wherein the polymer is selected from the group consisting of naturally occurring, synthetically-derived, covalently crosslinkable, ionically crosslinkable, hydrophilic, and combinations thereof.

6. The method of claim 1 , wherein the nerve graft is further modified into a structure selected from the group consisting of a suture, tube, sheet, film, scaffold, valve, limb replacement, tissue transplant, and joint for delivery into the body.

7. The method of claim 1 , wherein the step of washing the nerve graft tissue replacement comprises serial solutions of a buffered salt comprises three serial washes of 100 mM sodium and 50 mM phosphate for about 15 minutes each.

8. The method of claim 1 , wherein the nerve graft is harvested from mammalian cadaver.

9. The method of claim 8 , wherein the nerve graft is cleaned of fat and blood after harvesting and rinsed for several hours in deionized distilled water.

10. A native, neural cell-free tissue replacement nerve graft made by the method of:

soaking the nerve graft for at least six hours in a solution comprising one or more sulfobetaines;

washing the nerve graft in one or more solutions of a buffered salt;

extracting the nerve graft in a mixture of one or more sulfobetaines with an anionic surface-active detergent; and

washing the nerve graft in one or more solutions of a buffered salt to remove the excess anionic surface-active detergent, wherein the nerve graft is immunologically tolerated when implanted.

11. The cell-free neural tissue replacement of claim 10 , further comprising the step of:

adhering one or more components to the nerve graft before storing, wherein the components are selected from the group consisting of a cell, a polymer, a bioactive compound, and combinations thereof.

12. The cell-free neural tissue replacement of claim 11 , wherein the cell is selected from the group consisting of bone, cartilage, dermal, muscular, thyroidal, parathyroidal, lymphoid, pancreatic, urinary, digestive, hepatic, biliary, vascular, nervous, reproductive and combinations thereof.

13. The cell-free neural tissue replacement of claim 11 , wherein the cells are obtained from a donor, a host, from cell culture from a donor or a host, or cell cultures of established cells, tissue cells, or transformed cell lines.

14. The cell-free neural tissue replacement of claim 11 , wherein the bioactive compound is selected from the group consisting of a drug, protein, peptide, polysaccharide, fatty acid, nucleic acid, oligonucleotide, detectable agent, organic molecules, inorganic molecules or salts and combinations thereof that include natural or synthetic analogs, derivatives, or mimetic versions of the bioactive compound for therapeutic, prophylactic and diagnostic purposes.

15. The cell-free neural tissue replacement of claim 11 , wherein the polymer is selected from the group consisting of naturally occurring, synthetically-derived, covalently crosslinkable, ionically crosslinkable, hydrophilic, and combinations thereof.

16. The cell-free neural tissue replacement of claim 10 , wherein the nerve graft is further modified into a structure selected from the group consisting of a suture, tube, sheet, film, scaffold, valve, limb replacement, tissue transplant, and joint for delivery into the body.

17. The cell-free neural tissue replacement of claim 10 , wherein the step of washing the tissue replacement comprises serial solutions of a buffered salt comprises three serial washes of 100 mM sodium and 50 mM phosphate for about 15 minutes each.

18. The cell-free neural tissue replacement of claim 10 , wherein the nerve graft is harvested from mammalian cadaver.

19. The cell-free neural tissue replacement of claim 18 , wherein the nerve graft is cleaned of fat and blood after harvesting and rinsed for several hours in deionized distilled water.

20. An optimized acellular nerve graft that supports axonal regeneration, guides the axons toward the distal nerve end and is immunologically tolerated, wherein the nerve graft is made by the method of soaking the nerve graft for at least six hours in a solution comprising one or more sulfobetaines;

washing the nerve graft in one or more solutions of a buffered salt;

extracting the nerve graft in a mixture of one or more sulfobetaines with an anionic surface-active detergent; and

washing the nerve graft in one or more solutions of a buffered salt to remove the excess anionic surface-active detergent, wherein the acellular neural graft, is immunologically tolerated when implanted.

21. The acellular graft of claim 20 , further comprising the step of adhering one or more components to the neural graft before storing.

22. The acellular graft of claim 20 , further comprising a component selected from the group consisting of a cell, a polymer, a bioactive compound or combinations thereof.

23. The acellular graft of claim 20 , wherein the neural graft is stored at about 4 degrees centigrade in a sterile, buffered solution until use.

24. The method of claim 1 , wherein the nerve graft is an autograft, allograft, or xenograft.

25. The acellular nerve graft of claim 20 , wherein the nerve graft is an autograft, allograft, or xenograft.

26. A method for preparing a native, nerve cell-free tissue replacement nerve graft comprising the steps of:

soaking the nerve graft for at least six hours in a solution comprising sulfobetaine;

washing the nerve graft in one or more solutions of a buffered salt;

extracting the nerve graft in a mixture of one or more sulfobetaines with an anionic surface-active detergent;

washing the nerve graft in one or more solutions of a buffered salt to remove the excess anionic surface-active detergent, wherein the nerve graft is immunologically tolerated when implanted; and

adhering one or more components to the nerve graft before storing, wherein the components are selected from the group consisting of a cell, a polymer, a bioactive compound, and combinations thereof, wherein the cells are obtained from a donor, a host, from cell culture from a donor or a host, or cell cultures of established cells, tissue cells, or transformed cell lines.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded May 31, 2018
From: MIDCAP FUNDING IV TRUST; MIDCAP FINANCIAL TRUST
To: AXOGEN CORPORATION; AXOGEN, INC. FORMERLY KNOWN AS LECTEC CORPORATION
Reel/Frame 045952/0283 →
SECURITY INTEREST Recorded Nov 1, 2016
From: AXOGEN, INC. FORMERLY KNOWN AS LECTEC CORPORATION; AXOGEN CORPORATION
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 040189/0049 →
SECURITY INTEREST Recorded Nov 1, 2016
From: AXOGEN, INC. FORMERLY KNOWN AS LECTEC CORPORATION; AXOGEN CORPORATION
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 040189/0429 →
RELEASE OF SECURITY INTEREST OF REEL/FRAME 034173/0187 Recorded Oct 27, 2016
From: THREE PEAKS CAPITAL S.A.R.L.
To: AXOGEN CORPORATION; AXOGEN, INC. (FORMERLY KNOWN AS LECTEC CORPORATION)
Reel/Frame 040502/0018 →
CONFIRMATORY LICENSE Recorded Feb 18, 2015
From: THE UNIVERSITY OF TEXAS AT AUSTIN
To: NATIONAL SCIENCE FOUNDATION
Reel/Frame 035032/0504 →
SECURITY INTEREST Recorded Nov 14, 2014
From: AXOGEN CORPORATION
To: THREE PEAKS CAPITAL S.A.R.L.
Reel/Frame 034173/0187 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 5, 2014
From: SCHMIDT, CHRISTINE; HUDSON, TERRY
To: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Reel/Frame 033041/0542 →